Table of Contents
ALLEGAN, Mich. — Perrigo Co. is transferring its U.S. common stock listing to the New York Stock Exchange (NYSE) from the Nasdaq Global Select Market.
The company said Thursday that it expects to start trading on the NYSE on June 6 under its current stock symbol, "PRGO." Until the listing is transferred, Perrigo’s stock will continue to trade on Nasdaq.
To mark the switch, representatives of Perrigo will ring the NYSE opening bell on June 6 at 9:30 a.m. ET.
"We are looking forward to listing on the NYSE, as this change will provide increased visibility and enhanced services that will benefit our shareholders," stated Joseph Papa, Perrigo’s chairman and chief executive officer. "We remain committed to making quality health care more affordable for our customers and patients and continuing to increase shareholder value."
Perrigo develops, manufactures and distributes over-the-counter and generic prescription medications, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients (API). The company is the world’s largest manufacturer of OTC pharmaceuticals for the store-brand market.
"Perrigo and the NYSE are a perfect fit, and we’re thrilled to welcome one of the world’s leading health care suppliers to the world’s leading equities market," commented Duncan Niederauer, CEO of NYSE Euronext. "Perrigo was founded more than a century ago seeking to best serve and empower customers, continually innovate and deliver quality products. That vision, which remains in place today, set the stage for the company’s growth and global leadership. On behalf of my NYSE Euronext colleagues, I want to thank Joe Papa and the Perrigo board for choosing the NYSE. We look forward to building an outstanding partnership with the entire Perrigo team and the company’s shareholders."
